Research Article

Exemestane Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells and Promoting the Secretion of Interleukin 10

Ya-Hui Wang,1,2 Rong-Kun Li,3 Ying Fu,2 Jun Li,2 Xiao-Mei Yang,2 Yan-Li Zhang,2 Lei Zhu,2 Qin Yang,2 Jian-Ren Gu,1,2 Xin Xing,4 and Zhi-Gang Zhang2

1Shanghai Medical College of Fudan University, Shanghai 200032, China
2State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, China
3Department of Oncology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an 223300, China
4Department of Obstetrics and Gynecology, Fengxian Hospital, Shanghai 201499, China

Correspondence should be addressed to Xin Xing; Xingxin_01@live.cn and Zhi-Gang Zhang; zzhang@shsci.org

Received 5 September 2017; Accepted 23 October 2017; Published 10 December 2017

Academic Editor: Jian Song

Copyright © 2017 Ya-Hui Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Exemestane (EXE) is an irreversible steroidal aromatase inhibitor mainly used as an adjuvant endocrine therapy for postmenopausal women suffering from breast cancer. Besides inhibiting aromatase activity, EXE has multiple biological functions, such as antiproliferative, anti-inflammatory, and antioxidant activities which are all involved in hepatic fibrosis. Therefore, we investigated the role of EXE during the progress of hepatic fibrosis. The effect of EXE on liver injury and fibrosis were assessed in two hepatic fibrosis rat models, which were induced by either carbon tetrachloride (CCl4) or bile duct ligation (BDL). The influence of EXE treatment on activation and proliferation of primary rat hepatic stellate cells (HSCs) was observed in vitro. The results showed that EXE attenuated the liver fibrosis by decreasing the collagen deposition and α-SMA expression in vivo and inhibited the activation and proliferation of primary rat HSCs in vitro. Additionally, EXE promoted the secretion of antifibrotic and anti-inflammatory cytokine IL-10 in vivo and in HSC-T6 culture media. In conclusion, our findings reveal a new function of EXE on hepatic fibrosis and prompted its latent application in liver fibrotic-related disease.

1. Introduction

Liver fibrosis is a wound-healing response to chronic injury. In this process, the activation and phenotype change of hepatic stellate cells (HSCs) are the key cellular events. HSCs change from vitamin A storing quiescent cells to proliferative and contractile myofibroblast-like cells producing extracellular matrix (ECM) [1]. Hepatic fibrosis tends to occur in men and postmenopausal women but rare in premenopausal women [2, 3]. Numerous evidences reveal that estrogen is the underlying factor of this phenomenon [4–6]. Accumulating studies have demonstrated that estrogen has protective effects for hepatic fibrosis and cirrhosis by inhibiting the activation and proliferation of hepatic stellate cells [7–9]. But unfortunately, except for its beneficial aspect, estrogen can also promote the growth of some malignant tumors. For example, targeting estrogen is one of the current effective therapeutic strategies for breast cancer.

Exemestane (EXE), an aromatase inhibitor, can decrease estrogen levels by blocking estrogen synthesis in the adipose tissue [10]. Presently, EXE is widely applied as an adjuvant endocrine therapy for estrogen-receptor- (ER-) positive postmenopausal women to prevent breast cancer and for advanced breast cancer after treatment failure with tamoxifen [11, 12]. In addition, to inhibit aromatase activity, EXE also had strong antiproliferative effect and can increase the occurrence of autophagy [11, 12]. The latest report revealed that EXE had anti-inflammatory and antioxidant activities, probably unrelated to aromatase inhibition [13]. Even more, Masri et al. suggested that EXE could induce estrogen...
receptor alpha activity [14]. Theoretically, EXE may have a promoting function for hepatic fibrosis through diminishing the estrogen levels. However, almost no patients who took EXE underwent hepatic fibrosis and cirrhosis. A recent study showed that aromatase inhibitor EXE decreased radiation-induced lung fibrosis, suggesting that it has a protective effect [15]. Until now, there is no study to investigate the exact role of EXE during the hepatic fibrosis process. In the field of experimental liver fibrosis research, the two most commonly used animal models are carbon tetrachloride (CCL4) and bile duct ligation- (BDL-) induced hepatic fibrosis models. CCL4 is the most widely used hepatotoxin in the study of liver fibrosis and cirrhosis in rodents. In many aspects, it mimics human chronic disease associated with toxic damage. Common bile duct ligation is well-known to cause cholestatic liver injury and periportal biliary fibrosis. To explore the role of EXE in liver fibrosis process, we applied EXE in CCL4 and BDL-induced hepatic fibrosis rat models and investigated its effects on collagen deposition and fibrotic marker expression. We further revealed its underlying mechanisms by exploring its roles in HSC activation, proliferation, and in the secretion of inflammatory factors.

2. Results

2.1. EXE Suppresses CCL4-Induced Rat Hepatic Fibrosis and Attenuates Hepatic Injury. To directly investigate the role of EXE on hepatic fibrosis, CCL4-induced rat hepatic fibrosis model was established. Rats were treated with CCL4 for 8 weeks with or without EXE treatment. After the rats were sacrificed, the liver fibrosis degree was assessed by Sirius Red staining. Quantification of Sirius Red-stained collagen areas in images of rat liver tissues clearly showed that EXE-treated rats had less collagen deposition than control rats (Figure 1(a)). To further evaluate the function of EXE for liver injury, we detected the serum ALT and AST levels, which are the serological markers for liver fibrosis and liver function. We found that rats treated with EXE had a notable reduction of serum ALT and AST levels compared to rats without EXE treatment (Figure 1(b)). These data indicate that EXE has a protective effect on hepatic fibrosis and liver injury.

2.2. EXE Ameliorates BDL-Induced Hepatic Fibrogenesis and Hepatic Injury. To validate our primary results, EXE was administered in BDL-induced rat hepatic fibrosis model. Consistent with the results of CCL4-induced model, EXE remarkably ameliorated the progression of BDL-induced liver fibrosis, as illustrated in the Sirius Red-stained liver specimens (Figure 1(c)). The serum AST levels were significantly decreased in the EXE-treated group. However, the serum ALT levels of the EXE-treated group had no significant alteration compared to the control group (Figure 1(d)). Our finding is further convinced by BDL-induced rat hepatic fibrosis model. Thus, EXE can significantly inhibit hepatic fibrosis in vivo.

2.3. EXE Inhibits the Expression of Profibrogenic Markers. Meanwhile, the mRNA expression levels of Acta2, MMP13, Coll1a1, and TIMP1 were examined, which are all classical profibrogenic markers during liver fibrosis process [16, 17]. In CCL4-induced rat model, EXE significantly inhibited the expression levels of Acta2 and Coll1a1 and elevated the expression level of MMP13. Nevertheless, it had no obvious effect on TIMP1 expression (Figure 2(a)). Likewise, EXE significantly decreased the BDL-induced upregulation of Acta2, Coll1a1, and TIMP1, but had no obvious impact on MMP13 expression (Figure 2(b)).

2.4. EXE Inhibits HSC Activation and Proliferation In Vivo. Hepatic fibrosis is accompanied with the activation of hepatic stellate cells (HSCs) [18]. The activated HSCs increase the fibrillar extracellular matrix production and decrease the degradation and remodeling. To further explore the mechanism of EXE suppressing hepatic fibrosis, we performed immunohistochemical staining for α-SMA, a marker of HSC activation, and PCNA, a marker of cell proliferation in the rat liver samples from both EXE-treated and control groups. The results showed that EXE significantly decreased the expression of α-SMA in the liver and the α-SMA-positive HSCs mainly located in the septa of fibrotic liver (Figures 3(a) and 3(b)). The images of PCNA immunohistochemical staining revealed that the number of the PCNA-positive HSCs and hepatocytes in the liver of the EXE-treated rats was significantly reduced than that in the control rats (Figures 3(c) and 3(d)). The reduction of PCNA-positive hepatocytes also suggested that the EXE could attenuate liver injury. HSC activation and proliferation are key and symbolic events during the process of hepatic fibrosis [19]. Thereby, the inhibitory effect of EXE for HSC activation and proliferation in vivo might be the probable mechanism of its mitigation impact on liver fibrosis.

2.5. EXE Restraints rHSC Activation and Proliferation In Vitro. To further investigate whether the inhibitory effect of EXE on fibrogenesis was due to the inhibition of HSC activation and proliferation, we incubated freshly isolated HSCs (rHSCs) from rats with or without EXE. Then, we investigated the effect of EXE on rHSC activation and proliferation. There is a clear discrepancy in morphological appearance of rHSCs treated with 10 μM EXE for 4 days (Figure 4(a)); therefore, this concentration was performed for all treatments in vitro. rHSCs treated with 10 μM EXE expressed significantly less α-SMA fibers and showed an inactivation phenotype in morphology compared with controls (Figure 4(b)). In accordance with the results obtained in vivo, EXE markedly decreased the proliferation of rHSCs by EdU staining (Figure 4(c)). Furthermore, the mRNA expression levels of Acta2, Coll1a1, TIMP1, and Myh11, which are classical markers for HSC activation, were significantly reduced in EXE-treated rHSCs (Figure 4(d)).

2.6. EXE Promotes the Secretion of Antifibrotic Cytokine IL-10. Inflammation has a close relationship with chronic liver injury and hepatic fibrosis [20]. Numerous immunoregulatory cytokines are produced during the process of hepatic fibrosis and HSC activation. Among these cytokines, IL-10 has been proven to have a striking effect against liver injury
and fibrosis [21, 22], and IL-6 is a key profibrotic factor [23]. To elucidate whether IL-10 and IL-6 are involved in the suppressing effect of EXE on hepatic fibrosis, we detected their serum levels in the control group and EXE-treated group. The results showed that the level of IL-10 was higher in the EXE group than in the control group (Figure 5(a)). In contrast, the EXE group showed less IL-6 than that of the control group (Figure 5(b)). Since IL-10 and IL-6 were partly secreted from activated HSCs in the impaired liver, we examined the concentration of IL-10 and IL-6 in HSC-T6 cells culture media before and after treatment with 10 μM EXE. Likewise, EXE was also contributed to the secretion of IL-10, but not to the secretion of IL-6 in vitro (Figures 5(c) and 5(d)). Taken together, these data indicate that the antifibrotic effects of EXE are at least partially due to its anti-inflammatory activity.
3. Discussion

This study showed that treatment with EXE significantly attenuates CCl4 and BDL-induced hepatic fibrosis in male rats. EXE inhibited the activation and proliferation of HSCs in vitro and in vivo and promoted the secretion of antifibrotic cytokine IL-10. Our results explained why occurrence of hepatic fibrosis or cirrhosis is not elevated in breast cancer patients who were administered with EXE, though it suppresses estrogen, and revealed that EXE might be a potential drug for treatment of hepatic fibrosis or cirrhosis.

Hepatic fibrosis or cirrhosis is a common clinical situation that has various aetiologies and serious impairment for patients, but satisfactory therapies are still lacking. Sustained and exaggerated inflammation and hepatic stellate cell activation are the core processes during hepatic fibrosis initiation and progression [24]. EXE is a widely used drug for estrogen receptor-positive postmenopausal breast cancer patients. Our findings displayed its inhibitory effect.
in CCl4 and BDL-induced hepatic fibrosis rat models by suppressing HSC activation and proliferation. Thus, it might be very interesting to make further clinical analysis of EXE on hepatic fibrosis and cirrhosis prevention and therapy.

The roles of estrogen in hepatic fibrosis and cirrhosis are still controversial, but dominating evidences tend to support the idea that estrogen plays protective effects against hepatic fibrosis [5]. As expected, EXE should promote hepatic fibrosis as it is an aromatase inhibitor and can decrease the estrogen levels. Surprisingly, our results showed that EXE significantly suppressed hepatic fibrosis in vivo. And in vitro, our assay displayed that EXE also inhibited HSC activation. This suggested that the antifibrotic effect of EXE is not related to aromatase inhibition, but due to its inhibitory effects on HSC activation and proliferation.

Liver inflammation is the hallmark of early-stage liver fibrosis, ultimately resulting in HSC activation and ECM deposition. In the numerous immunoregulatory cytokines, IL-10 is a potent anti-inflammatory cytokine. It can repress proinflammatory responses and limit unnecessary tissue disruptions caused by inflammation. By ELISA analysis,
we found that IL-10 level was significantly elevated in the serum of EXE-treated rats. Therefore, it revealed that modulating anti-inflammatory cytokines might partly be the mechanisms of antifibrotic effects of EXE. However, inflammatory factors are mainly secreted by local inflammatory cells in the liver, such as Kupffer cells and lymphocytes. Hence, further researches about EXE on inflammatory cell infiltration and anti-inflammatory cytokine secretion are under investigation.

Figure 4: Effects of EXE on HSC activation and proliferation in vitro. (a) Bright field images of the control and EXE-treated HSCs at day 4 of culture. Scale bar 50 μm. (b) EXE-treated and control cells were fixed at day 4 and immunostained with α-SMA antibodies. Scale bar 50 μm. (c) At day 2, EXE-treated and control HSCs were exposed to EdU and fixed 2 days later and stained with Azide488 to visualize the DNA incorporated EdU. The percentage of EdU-positive cells was determined from three independent experiments. Scale bar 50 μm. (d) mRNA levels of Acta2, Myh11, Coll1a1, and Timp1 in HSCs with or without EXE treatment were determined by qPCR (10 rats/group). Data were expressed as means ± SD. *P < 0.05, **P < 0.01.

In summary, our in vitro and in vivo findings demonstrated that treatment with EXE attenuates the process of hepatic fibrosis by inhibiting the activation of HSCs and upregulating the secretion of IL-10. To our knowledge, this study is the first to show the antifibrotic effects of EXE. As a widely applied medicine for breast cancer, EXE has shown no significant side-effects on renal or liver functions [25]. Therefore, EXE might be useful as an antifibrotic agent in chronic liver diseases. There are many common processes...
existing in different organ fibrotic diseases, including interstitial cell activation and inflammatory factor dysregulation. Thereby, EXE might also have extensive potential application in other different organ fibrotic diseases, such as renal fibrosis, pulmonary fibrosis, scleroderma, and so on.

4. Methods

4.1. Cell Culture and Reagents. HSC-T6 cells, an immortalized rat HSC cell line, were obtained from the cell bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, USA) supplemented with 10% fetal calf serum (HyClone, Australia), 100 U/ml penicillin, and 100 μg/ml streptomycin. EXE was obtained from Sigma (St. Louis, USA).

4.2. Animal Experiments. The hepatic fibrosis models of male Sprague-Dawley (SD) rats were induced by CCl₄ and BDL, respectively. For CCl₄-induced hepatic fibrosis model, 20 SD rats about 200 g were given intraperitoneal injections of 1 ml CCl₄/kg body weight diluted 1:1 in olive oil twice weekly for 8 weeks. One week after the first injection of CCl₄, SD rats were randomly divided into two groups: CCl₄ group and EXE group (EXE + CCl₄) (n = 10 in each group), and started to treat with EXE. For BDL liver fibrosis model, 20 male SD rats were also divided into two groups one week after the rats underwent BDL (n = 10 in each group) and started to receive EXE or vehicle treatment. EXE was suspended in normal saline solution and administered twice a week by intraperitoneal injection at 4 mg/kg body weight. Rats were sacrificed 48 hours after the last EXE injection. All rat livers were fixed in formaldehyde or immediately frozen in liquid nitrogen. Rats were manipulated and housed according to protocols approved by the East China Normal University Animal Care Commission. All animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences and published by the National Institutes of Health.

4.3. Isolation and Culturing of Rat HSCs. Male SD rats (250 to 300 g) were used to isolate and purify HSCs. Rat HSC isolation method was a modification of the previously described method [26]. Rat HSCs were isolated using a two-step collagenase/pronase E perfusion of rat livers, followed by 18% Nycodenz two-layer discontinuous density-gradient centrifugation. After isolation, cells were suspended in DMEM with 10% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin, plated on plastic dishes (Corning, Jamestown, NY).
Table 1: Oligonucleotide sequences of primers used in real-time PCR.

| Gene   | Sequences (5’→3’)                  |
|--------|-----------------------------------|
| MMP13  | F:GGTTGAGGCTGAAGGTGTTTTG          |
|        | R:CTCGTATGACGATCAGCATG           |
|        | F:CCAGCTTGGTGTGGATT              |
|        | R:CCAGGTCCTCCAGGAACACC           |
| TIMP1  | F:GGACCACTTATACCAAGGTT           |
|        | R:GTCACTCTCAGATTGCAGAAGAGT      |
| Acta2  | F:GGGAGCTCAAAGTGTGTGAGG          |
|        | R:CGGCACTAGTCAGGAAAGGAT          |
| Myh11  | F:GTAAGAGAAGAGATGGCTCA           |
|        | R:TGTAGTTTCTGCTGCGGACCTT         |
|        | F:GTCACTGATGTCTGGAGGCTCT         |
| GAPDH  | R:GGTTCACACCCATCACAAACA         |

USA), and cultured at 37°C in a humidified atmosphere with 5% CO₂ and 95% air. Culture medium was renewed 24 hours after plating.

**4.4. Measurement of Liver Enzymes and Cytokines.** Rat blood was collected in Eppendorf tubes and standing in 4°C overnight. The serums were separated by centrifugation at 3000 r/min for 20 minutes and stored at −80°C. Serum ALT and AST activities were detected with ALT and AST kits (Shen Suo You Fu Co. Ltd., Shanghai, China) by an automated analyzer. To study the effects of EXE on anti-inflammatory cytokines, such as IL-10 and IL-6, rat blood specimens were fixed in 10% formalin. To detect collagen fibers, paraffin-embedded liver sections were stained in 0.1% Sirius Red F3BA in a saturated picric acid solution. Randomly selected five fields from each section were photographed and analyzed. Red staining areas were quantified using NIH Imagej software (http://rsb.info.nih.gov/ij/) and expressed as a percentage of total analyzed areas. For immunohistochemical staining, all tissue samples were fixed in phosphate-buffered neutral formalin, embedded in paraffin, and then cut into 5-μm thick sections. Tissue sections were deparaffinized and rehydrated and then incubated with 0.3% hydrogen peroxide/phosphate-buffered saline for 30 minutes and blocked with 10% BSA. Slides were first incubated using the mouse-anti-a-smooth muscle actin (α-SMA) antibody (clone 1A4; Sigma-Aldrich, USA) and a rabbit-anti-proliferating cell nuclear antigen (PCNA) antibody (ab29, Abcam, USA), respectively, at 4°C overnight with optimal dilution, labeled by HRP second antibody (A-11059 and A-21245, Thermo Scientific, USA) at room temperature for 1 hour, incubated with DAB substrate liquid (Thermo Scientific), and counterstained with hematoxylin. All sections were observed and photographed with a microscope. α-SMA-positive staining areas were quantified using Imagej software and presented as a percentage of total analyzed areas. PCNA-positive and negative cells were counted at ×400 magnification. All reactive cells were counted as positive regardless of the intensity of staining. For HSCs, PCNA-positive cells were counted and expressed. For hepatocytes, in each picture, all cells were counted and the percentage of positive hepatocytes was determined.

**4.8. Statistical Analysis.** Data are expressed as means ± standard deviation of at least three independent experiments unless indicated otherwise. Groups are compared using a two-tailed Student t-test. P < 0.05 is considered statistically significant.

**Conflicts of Interest**

The authors declare no competing financial interests.

**Authors’ Contributions**

Xin Xing and Zhi-Gang Zhang conceived and designed the experiments. Ya-Hui Wang and Rong-Kun Li performed the experiments and drafted the manuscript. Qin Yang was involved in the data analysis. Xiao-Mei Yang, Yan-Li Zhang, and Lei Zhu provided technical assistance. All authors have reviewed and approved the final manuscript. Ya-Hui Wang and Rong-Kun Li contributed equally to this work.

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (no. 81500461 and no. 81502382),
References

[1] D. Li and S. L. Friedman, “Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy,” *Journal of Gastroenterology and Hepatology*, vol. 14, no. 7, pp. 618–633, 1999.

[2] S. H. Yeh and P. J. Chen, “Gender disparity of hepatocellular carcinoma: the roles of sex hormones,” *Oncology*, vol. 78, no. 1, p. 172–179, 2010.

[3] D. M. Bissell, “Sex and hepatic fibrosis,” *Hepatology*, vol. 29, no. 3, pp. 988–989, 1999.

[4] D. L. White, S. Tavakoli-Tabasi, J. Kuzniarek, R. Pascua, D. J. Ramsey, and H. B. El-Serag, “Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males,” *Hepatology*, vol. 55, no. 3, pp. 759–768, 2011.

[5] I. Shimizu, “Impact of oestrogens on the progression of liver disease,” *Liver International*, vol. 23, no. 1, pp. 63–69, 2003.

[6] I. Shimizu and S. Ito, “Protection of estrogens against the progression of chronic liver disease,” *Hepatology Research*, vol. 37, no. 4, pp. 239–247, 2007.

[7] H. Volzke, S. Schwarz, S. E. Baumeister et al., “Menopausal status and hepatic steatosis in a general female population,” *Gut*, vol. 56, no. 4, pp. 594–595, 2007.

[8] Q. H. Liu, D. G. Li, X. Huang, C. H. Zong, Q. F. Xu, and H. M. Lu, “Suppressive effects of 17β-estradiol on hepatic fibrosis in CCl4-induced rat model,” *World Journal of Gastroenterology*, vol. 10, no. 9, pp. 1315–1320, 2004.

[9] M. Yasuda, I. Shimizu, M. Shiba, and S. Ito, “Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats,” *Hepatology*, vol. 29, no. 3, pp. 719–727, 1999.

[10] E. di Salle, G. Ornati, D. Giudici, M. Lassus, T. R. Evans, and R. C. Coombe, “Exemestane (FCE 24304), a new steroidal aromatase inhibitor,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 43, no. 1-3, pp. 137–143, 1992.

[11] A. Koutrou, E. Giannopoulou, I. Kritikou et al., “Antiproliferative effect of exemestane in lung cancer cells,” *Molecular Cancer*, vol. 8, no. 1, p. 109, 2009.

[12] C. Amaral, M. Borges, S. Melo, E. T. da Silva, G. Correia-da-Silva, and N. Teixeira, “Apoptosis and autophagy in breast cancer cells following exemestane treatment,” *PLoS One*, vol. 7, no. 8, article e42398, 2012.

[13] H. Liu and P. Talalay, “Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 47, pp. 19065–19070, 2013.

[14] S. Masri, K. Lui, S. Phung et al., “Characterization of the weak estrogen receptor alpha agonistic activity of exemestane,” *Breast Cancer Research and Treatment*, vol. 116, no. 3, pp. 461–470, 2008.

[15] A. Y. Altinok, S. Yildirim, T. Altug et al., “Aromatase inhibitors decrease radiation-induced lung fibrosis: results of an experimental study,” *The Breast*, vol. 28, pp. 174–177, 2016.

[16] Y. Takahara, M. Takahashi, H. Wagatsuma et al., “Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis,” *World Journal of Gastroenterology*, vol. 12, no. 40, pp. 6473–6499, 2006.

[17] S. De Minicis, E. Seki, H. Uchinami et al., “Gene expression profiles during hepatitic stellate cell activation in culture and in vivo,” *Gastroenterology*, vol. 132, no. 5, pp. 1937–1946, 2007.

[18] W. Goessling, “Hepatic stellate cells and cirrhosis: fishing for cures,” *Hepatology*, vol. 56, no. 5, pp. 1596–1598, 2012.

[19] H. L. Reeves and S. L. Friedman, “Activation of hepatic stellate cells - a key issue in liver fibrosis,” *Frontiers in Bioscience*, vol. 7, no. 1-3, pp. d808–d826, 2002.

[20] S. L. Friedman, “Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications,” *Nature Reviews Gastroenterology and Hepatology*, vol. 1, no. 2, pp. 98–105, 2004.

[21] Y. G. Suh, J. K. Kim, J. S. Byun et al., “CD11b+ Gr1+ bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice,” *Hepatology*, vol. 56, no. 5, pp. 1902–1912, 2012.

[22] L. J. Zhang, W. D. Zheng, Y. X. Chen et al., “Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis,” *Hepatology*, vol. 54, no. 79, pp. 2092–2098, 2007.

[23] M. Natsume, H. Tsuji, A. Harada et al., “Attenuated liver fibrosis and depressed serum albumin levels in carbon tetrachloride-treated IL-6-deficient mice,” *Journal of Leukocyte Biology*, vol. 66, no. 4, pp. 601–608, 1999.

[24] H. S. Yi and W. I. Jeong, “Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?,” *Journal of Gastroenterology and Hepatology*, vol. 28, Supplement 1, pp. 99–104, 2013.

[25] K. Van Asten, P. Neven, A. Lintermans, H. Wildiers, and R. Paridaens, “Aromatase inhibitors in the breast cancer clinic: focus on exemestane,” *Endocrine-Related Cancer*, vol. 21, no. 1, pp. R31–R49, 2014.

[26] R. Weiskirchen and A. M. Gressner, “Isolation and culture of hepatic stellate cells,” *Methods in Molecular Medicine*, vol. 117, pp. 99–113, 2005.